Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZBIO Zenas BioPharma Inc.

盘后交易 01-21 18:17:46 EST

19.59

-1.29

-6.18%

盘后19.53

-0.06-0.31%

17:11 EST

最高21.39	最低19.40	成交量83.08万
今开20.87	昨收20.88	日振幅9.53%
总市值10.52亿	流通市值4.13亿	总股本5,368万
成交额1,646万	换手率3.94%	流通股本2,107万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":19.59,"timestamp":1769029200000,"preClose":20.88,"halted":0,"volume":830846,"hourTrading":{"tag":"盘后","latestPrice":19.53,"preClose":19.59,"latestTime":"17:11 EST","volume":3514,"amount":68803.712376,"timestamp":1769033484704,"change":-0.06,"changeRate":-0.003063,"amplitude":0.017866},"delay":0,"changeRate":-0.06178160919540226,"floatShares":21071865,"shares":53679166,"eps":-4.527832,"marketStatus":"盘后交易","change":-1.29,"latestTime":"01-21 18:17:46 EST","open":20.87,"high":21.39,"low":19.4,"amount":16455037.96536,"amplitude":0.095307,"askPrice":20,"askSize":30,"bidPrice":19.05,"bidSize":21,"shortable":3,"etf":0,"ttmEps":-4.527832,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1769043600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":20.88,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":20.85,"preClose":20.88,"latestTime":"09:10 EST","volume":1668,"amount":34423.726968,"timestamp":1769004611235,"change":-0.03,"changeRate":-0.001437,"amplitude":0.042912},"postHourTrading":{"tag":"盘后","latestPrice":19.53,"preClose":19.59,"latestTime":"17:11 EST","volume":3514,"amount":68803.712376,"timestamp":1769033484704,"change":-0.06,"changeRate":-0.003063,"amplitude":0.017866},"volumeRatio":0.801132,"impliedVol":1.6992,"impliedVolPercentile":0.9921},"requestUrl":"/m/hq/s/ZBIO","defaultTab":"news","newsList":[{"id":"1195864515","title":"Zenas BioPharma股价因免疫疾病药物后期数据不佳而跌至逾四个月低点，日内跌幅达55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195864515","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195864515?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:30","pubTimestamp":1767627041,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) 股价近日遭遇重挫，创下逾四个月以来的新低。此次股价大幅下跌的主要原因是其免疫疾病药物的后期临床试验数据未达市场预期，导致投资者信心受挫。截至最新交易时段，该公司股价当日跌幅高达55%，反映出市场对其药物研发前景的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1165846039","title":"Zenas BioPharma公布Obexelimab治疗IgG4相关疾病3期INDIGO注册试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1165846039","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165846039?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:06","pubTimestamp":1767614762,"startTime":"0","endTime":"0","summary":"Zenas BioPharma宣布，其药物Obexelimab在针对免疫球蛋白G4相关疾病（IgG4-RD）的3期INDIGO注册试验中取得了积极成果。该试验达到了主要终点，显示出显著疗效和良好安全性，为后续监管申报奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1133394639","title":"InnoCare Pharma宣布Orelabrutinib（Btk抑制剂）在系统性红斑狼疮的2B期研究中实现主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1133394639","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133394639?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:07","pubTimestamp":1765800457,"startTime":"0","endTime":"0","summary":"InnoCare Pharma宣布在针对系统性红斑狼疮的Orelabrutinib（Btk抑制剂）2B期研究中实现了主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1142056905","title":"Zenas BioPharma：Obexelimab三期Indigo试验在免疫球蛋白G4相关疾病（IgG4-RD）中的初步结果预计将在年末公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1142056905","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142056905?lang=zh_cn&edition=full","pubTime":"2025-11-12 20:13","pubTimestamp":1762949593,"startTime":"0","endTime":"0","summary":"Zenas BioPharma：Obexelimab三期Indigo试验在免疫球蛋白G4相关疾病（IgG4-RD）中的初步结果预计将在年末公布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1122038621","title":"Zenas Biopharma公布Obexelimab在复发性多发性硬化症II期Moonstone试验中取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1122038621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122038621?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:08","pubTimestamp":1761563296,"startTime":"0","endTime":"0","summary":"Zenas Biopharma公布Obexelimab在复发性多发性硬化症II期Moonstone试验中取得积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1165438252","title":"Zenas Biopharma预计将在2026年第一季度启动Orelabrutinib针对继发渐进性多发性硬化症患者的全球三级临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1165438252","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165438252?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:08","pubTimestamp":1761563293,"startTime":"0","endTime":"0","summary":"Zenas Biopharma预计将在2026年第一季度启动Orelabrutinib针对继发渐进性多发性硬化症患者的全球三级临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1122167777","title":"Zenas Biopharma向SEC申请最多出售630万股普通股的架构筹资","url":"https://stock-news.laohu8.com/highlight/detail?id=1122167777","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122167777?lang=zh_cn&edition=full","pubTime":"2025-10-22 04:49","pubTimestamp":1761079748,"startTime":"0","endTime":"0","summary":"Zenas Biopharma向SEC申请最多出售630万股普通股，出售股东为卖方。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"1182685701","title":"Zenas BioPharma：市场发行招股说明书 涵盖根据销售协议可能发行的最多2亿美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1182685701","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182685701?lang=zh_cn&edition=full","pubTime":"2025-10-09 04:37","pubTimestamp":1759955838,"startTime":"0","endTime":"0","summary":"Zenas BioPharma：市场发行招股说明书 涵盖根据销售协议可能发行的最多2亿美元普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"1146091822","title":"Zenas BioPharma Inc.新型口服IL-17AA/AF抑制剂和口服透脑TYK2抑制剂预计2026年启动一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1146091822","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146091822?lang=zh_cn&edition=full","pubTime":"2025-10-08 17:06","pubTimestamp":1759914392,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.的新型口服IL-17AA/AF抑制剂和口服透脑TYK2抑制剂预计将于2026年开始一期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239","BK4139","ZBIO"],"gpt_icon":0},{"id":"1121287790","title":"Zenas BioPharma Inc.与诺诚健华宣布签署许可协议，授予Zenas三项自身免疫候选产品的权益，其中包括BTK抑制剂奥雷巴替尼，该药物正处于多发性硬化症三期临床开发阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1121287790","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121287790?lang=zh_cn&edition=full","pubTime":"2025-10-08 17:00","pubTimestamp":1759914020,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.与诺诚健华宣布签署许可协议，授予Zenas三项自身免疫候选产品的权益，其中包括BTK抑制剂奥雷巴替尼，该药物正处于多发性硬化症三期临床开发阶段","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK0239","ZBIO","688428"],"gpt_icon":0},{"id":"1170408200","title":"诺诚健华表示总支付款项连同研发、监管里程碑及商业化里程碑付款超过20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170408200","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170408200?lang=zh_cn&edition=full","pubTime":"2025-10-08 16:58","pubTimestamp":1759913894,"startTime":"0","endTime":"0","summary":"诺诚健华宣布，包括研发里程碑付款、监管里程碑付款和商业化里程碑付款在内的总支付款项已超过20亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","688428","BK0239","BK4139"],"gpt_icon":0},{"id":"1136169257","title":"异动解读 | 生物科技新星Zenas BioPharma首秀大涨11.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136169257","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136169257?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:00","pubTimestamp":1726246829,"startTime":"0","endTime":"0","summary":"今日,生物科技公司Zenas BioPharma Inc. 在纳斯达克成功完成IPO,股价大涨11.71%,引发市场关注。当日Zenas IPO发行价为17美元,开盘股价则为18.35美元,较发行价溢价8%。Zenas在本次IPO中发行1320万股,募集资金2.25亿美元,超过了原计划规模。随着美国IPO新股市场近期回温,投资者对Zenas这样前景可期的生物科技股青睐有加,均有望成为推动其当日首秀股价大涨的重要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZBIO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":-0.032},{"period":"1month","weight":-0.4224},{"period":"3month","weight":-0.1432},{"period":"6month","weight":0.2794},{"period":"1year","weight":1.6599},{"period":"ytd","weight":-0.425}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zenas BioPharma, Inc.最初于2019年11月12日在开曼注册成立，名称为Zenas BioPharma（开曼）Limited。2023年8月2日，该公司在特拉华州成立，同时将其名称从Zenas BioPharma（Cayman）Limited更改为Zenas BioPharma, Inc.。他们是一家临床阶段的全球生物制药公司，致力于为有需要的患者开发和商业化基于免疫的变革疗法。随着对自身免疫性疾病发病机制的不断了解，以及有前景的基于免疫学的药理学靶点的扩展，他们正在建立一家专注于免疫学和炎症（“I&I”）的生物制药公司。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Zenas BioPharma Inc.(ZBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Zenas BioPharma Inc.(ZBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}